EA200501549A1 - Применение экспрессирующего вектора, кодирующего ингибитор il-18, для лечения и/или профилактики заболевания сердца и способ лечения заболевания сердца - Google Patents

Применение экспрессирующего вектора, кодирующего ингибитор il-18, для лечения и/или профилактики заболевания сердца и способ лечения заболевания сердца

Info

Publication number
EA200501549A1
EA200501549A1 EA200501549A EA200501549A EA200501549A1 EA 200501549 A1 EA200501549 A1 EA 200501549A1 EA 200501549 A EA200501549 A EA 200501549A EA 200501549 A EA200501549 A EA 200501549A EA 200501549 A1 EA200501549 A1 EA 200501549A1
Authority
EA
Eurasian Patent Office
Prior art keywords
heart disease
inhibitor
prevention
treating
treatment
Prior art date
Application number
EA200501549A
Other languages
English (en)
Other versions
EA010180B1 (ru
Inventor
Чарльз Динарелло
Бенджамин Померантц
Леонид Резников
Альден Харкен
Йоланд Шватшко
Original Assignee
Апплайд Резеч Системз Арс Холдинг Н. В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Апплайд Резеч Системз Арс Холдинг Н. В. filed Critical Апплайд Резеч Системз Арс Холдинг Н. В.
Publication of EA200501549A1 publication Critical patent/EA200501549A1/ru
Publication of EA010180B1 publication Critical patent/EA010180B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Настоящее изобретение относится к применению экспрессирующего вектора, содержащего последовательность, кодирующую ингибитор IL-18, для приготовления лекарственного средства для лечения и/или профилактики заболевания сердца, в частности ишемической болезни сердца. Рассматривается также способ лечения заболевания сердца, предусматривающий введение нуждающемуся хозяину эффективного ингибирующего количества ингибитора IL-18.
EA200501549A 2001-01-29 2002-01-28 Применение ингибитора il-18 для приготовления лекарственного средства для лечения и/или профилактики кардиомиопатии EA010180B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01101959 2001-01-29

Publications (2)

Publication Number Publication Date
EA200501549A1 true EA200501549A1 (ru) 2006-04-28
EA010180B1 EA010180B1 (ru) 2008-06-30

Family

ID=8176323

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200300844A EA006767B1 (ru) 2001-01-29 2002-01-28 Применение ингибитора il-18 для приготовления лекарственного средства для лечения и/или профилактики заболевания сердца
EA200501549A EA010180B1 (ru) 2001-01-29 2002-01-28 Применение ингибитора il-18 для приготовления лекарственного средства для лечения и/или профилактики кардиомиопатии

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA200300844A EA006767B1 (ru) 2001-01-29 2002-01-28 Применение ингибитора il-18 для приготовления лекарственного средства для лечения и/или профилактики заболевания сердца

Country Status (32)

Country Link
US (1) US20040234523A1 (ru)
EP (1) EP1355668B1 (ru)
JP (2) JP4860897B2 (ru)
KR (1) KR100857376B1 (ru)
CN (1) CN1326562C (ru)
AR (1) AR032422A1 (ru)
AT (1) ATE380558T1 (ru)
BG (1) BG66483B1 (ru)
BR (1) BR0206819A (ru)
CA (1) CA2435466C (ru)
CY (1) CY1107203T1 (ru)
CZ (1) CZ305653B6 (ru)
DE (1) DE60224004T2 (ru)
DK (1) DK1355668T3 (ru)
EA (2) EA006767B1 (ru)
EE (1) EE05534B1 (ru)
ES (1) ES2295332T3 (ru)
HK (1) HK1062810A1 (ru)
HR (1) HRP20030609A2 (ru)
HU (1) HU229164B1 (ru)
IL (2) IL157024A0 (ru)
ME (1) ME00549B (ru)
MX (1) MXPA03006776A (ru)
NO (1) NO331083B1 (ru)
PL (1) PL213568B1 (ru)
PT (1) PT1355668E (ru)
RS (1) RS51125B (ru)
SI (1) SI1355668T1 (ru)
SK (1) SK287620B6 (ru)
UA (1) UA80676C2 (ru)
WO (1) WO2002060479A1 (ru)
ZA (1) ZA200305439B (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI373343B (en) 2000-02-10 2012-10-01 Abbott Gmbh & Co Kg Antibodies that bind human interleukin-18 and methods of making and using
WO2002031115A2 (en) 2000-10-11 2002-04-18 Viron Therapeutics, Inc. Nucleic acid molecules and polypeptides for immune modulation
US7718368B2 (en) 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
SI1622939T1 (sl) 2003-05-13 2012-06-29 Merck Serono Sa Akrivne variante il-18 vezavnega proteina in medicinske uporabe le-tega
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
JP4961559B2 (ja) * 2004-03-11 2012-06-27 友昭 星野 インターロイキン１８阻害剤を有効成分とする疾患の予防又は治療剤
PL2267024T3 (pl) 2005-06-03 2012-10-31 Ares Trading Sa Wytwarzanie rekombinowanego białka wiążącego IL-18
PL1891088T3 (pl) 2005-06-10 2012-03-30 Ares Trading Sa Sposób oczyszczania białka wiążącego IL-18
AU2008324814B2 (en) * 2007-11-05 2013-05-16 Solventum Intellectual Properties Company Identification of tissue for debridement
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
SG11201601717VA (en) * 2013-09-05 2016-04-28 Ab2 Bio Sa Il-18 binding protein (il-18bp) in inflammatory diseases
AU2016227644B2 (en) * 2015-03-05 2022-06-16 Ab2 Bio Sa IL-18 Binding Protein (IL-18BP) and antibodies in inflammatory diseases
US11091795B2 (en) 2016-07-11 2021-08-17 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for diagnosing and treating arrhythmias

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) * 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
NZ322197A (en) * 1995-11-21 1999-02-25 Yamanouchi Pharma Co Ltd Pyrido[2,3-d] pyrimidine derivatives and pharmaceutical compositions thereof
EP0929311B8 (en) * 1996-09-12 2006-02-01 Idun Pharmaceuticals, Inc. INHIBITION OF APOPTOSIS USING INTERLEUKIN-1 beta-CONVERTING ENZYME (ICE)/CED-3 FAMILY INHIBITORS
EP0942925B1 (en) * 1996-12-06 2006-11-22 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1 beta converting enzyme
CA2282845A1 (en) * 1997-03-18 1998-09-24 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
DE19743687C1 (de) * 1997-10-06 1998-11-26 Henkel Kgaa Detergensgemische und deren Verwendung
AU4961499A (en) * 1998-06-26 2000-01-17 Eli Lilly And Company 5-HT1f agonists
BR9816013A (pt) * 1998-09-01 2003-01-21 Hayashibara Biochem Lab Proteìna de ligação de interleucina-18
EP1022027A1 (en) * 1999-01-22 2000-07-26 Applied Research Systems ARS Holding N.V. Tumor necrosis factor antagonists and their use in endometriosis
KR20010110667A (ko) * 1999-03-16 2001-12-13 추후보정 치환 2-아미노벤즈아미드 카스파제 저해제 및 그것의 용도
WO2000061542A1 (en) * 1999-04-09 2000-10-19 Cytovia, Inc. Caspase inhibitors and the use thereof
AU6078500A (en) * 1999-07-09 2001-01-30 Amgen, Inc. Combination therapy for conditions leading to bone loss
TWI373343B (en) * 2000-02-10 2012-10-01 Abbott Gmbh & Co Kg Antibodies that bind human interleukin-18 and methods of making and using
BRPI0110506B8 (pt) * 2000-05-05 2021-05-25 Applied Res Systems Ars Holding N V uso de inibidores de il-18 para o tratamento e/ou prevenção da aterosclerose
WO2002032374A2 (en) * 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders

Also Published As

Publication number Publication date
YU57803A (sh) 2006-05-25
PL366802A1 (en) 2005-02-07
CY1107203T1 (el) 2012-11-21
PT1355668E (pt) 2008-01-04
UA80676C2 (en) 2007-10-25
HU229164B1 (en) 2013-09-30
CZ20032335A3 (en) 2004-07-14
HUP0303306A2 (hu) 2004-01-28
JP2009102354A (ja) 2009-05-14
BG66483B1 (bg) 2015-03-31
CN1499982A (zh) 2004-05-26
EA200300844A1 (ru) 2003-12-25
ATE380558T1 (de) 2007-12-15
CA2435466A1 (en) 2002-08-08
EE05534B1 (et) 2012-04-16
ME00549B (me) 2011-10-10
EP1355668A1 (en) 2003-10-29
SK287620B6 (sk) 2011-04-05
BG108128A (bg) 2004-11-30
EA010180B1 (ru) 2008-06-30
CN1326562C (zh) 2007-07-18
DE60224004D1 (de) 2008-01-24
DK1355668T3 (da) 2008-05-05
IL157024A0 (en) 2004-02-08
SI1355668T1 (sl) 2008-06-30
NO20033228L (no) 2003-09-26
CA2435466C (en) 2012-04-03
AR032422A1 (es) 2003-11-05
CZ305653B6 (cs) 2016-01-27
HUP0303306A3 (en) 2005-12-28
HRP20030609A2 (en) 2005-06-30
IL157024A (en) 2014-02-27
EE200300328A (et) 2003-10-15
JP4860897B2 (ja) 2012-01-25
EP1355668B1 (en) 2007-12-12
NO331083B1 (no) 2011-10-03
JP2004522748A (ja) 2004-07-29
WO2002060479A1 (en) 2002-08-08
RS51125B (sr) 2010-10-31
PL213568B1 (pl) 2013-03-29
KR20030070143A (ko) 2003-08-27
US20040234523A1 (en) 2004-11-25
NO20033228D0 (no) 2003-07-16
KR100857376B1 (ko) 2008-09-05
DE60224004T2 (de) 2009-07-23
HK1062810A1 (en) 2004-11-26
ES2295332T3 (es) 2008-04-16
MXPA03006776A (es) 2003-10-24
BR0206819A (pt) 2004-02-03
ZA200305439B (en) 2004-07-15
EA006767B1 (ru) 2006-04-28
SK10892003A3 (sk) 2004-02-03

Similar Documents

Publication Publication Date Title
CY1109191T1 (el) Μια νεα χρηση της δεφεριπρονης
EA200501549A1 (ru) Применение экспрессирующего вектора, кодирующего ингибитор il-18, для лечения и/или профилактики заболевания сердца и способ лечения заболевания сердца
DE60236413D1 (de) Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
CY1109242T1 (el) Θεραπευτικοι παραγοντες χρησιμοι για θεραπεια πονου
EA200401240A1 (ru) Применение ингибиторов il-18 для лечения и/или профилактики заболеваний периферических сосудов
ATE254461T1 (de) Behandlung von augenschmerzen
WO2002002518A3 (en) Compounds to treat alzheimer's disease
GB0223040D0 (en) Therapeutic compounds
WO2002002520A8 (en) Compounds to treat alzheimer's disease
DE602006010442D1 (de) Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von schmerzen
DE60115433D1 (de) Verfahren zur behandlung von chronischen geschwüren
TW200505473A (en) Compositions and methods for treatment of psoriasis
MXPA04003773A (es) Uso de leptina para tratar lipoatrofia humana y metodo para determinar la predisposicion a dicho tratamiento.
BR0310061A (pt) Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
CY1105545T1 (el) Θεραπεια στατινης για ενισχυση της διατηρησης νοητικης λειτουργιας
ATE357912T1 (de) Intrakorporelle medikamente zur hoch- energetischen phototherapeutischen behandlung von krankheiten
ATE499933T1 (de) Verwendung von betain zur behandlung von claudicatio intermittens
EA200601238A1 (ru) Медикаменты для профилактики и лечения бромидроза и для улучшения запаха тела
NO20033541L (no) Anvendelse av fosfodiesteraseinhibitorer av type 4 ved hjertemuskelsykdommer
TNSN06147A1 (en) Use of cathepsin k inhibitors for treating of severe bone loss diseases
ATE270110T1 (de) Arzneimittel enthaltend tissue inhibitor of metalloproteinases-2 (timp-2) als osteoanabol wirksame substanz
SE0100873D0 (sv) Method of treatment
DE60108775T8 (de) Methode zur behandlung von schlaganfall
TR199801801T2 (xx) Madde k�t�ye kullan�m�n�n tedavisi.
RU94044455A (ru) Средство для усиления функции макрофага и лечения человека с ослабленным иммунитетом

Legal Events

Date Code Title Description
PC1A Registration of transfer to a eurasian application by force of assignment
PD4A Registration of transfer of a eurasian patent in accordance with the succession in title
MK4A Patent expired

Designated state(s): RU